NCT00107978已完成3 期
A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus
Cumberland Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 1,035 人开始时间: 2005年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,035
- 试验地点
- 1
- 主要终点
- Clinical Response
研究概览
简要总结
Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a diagnosis of one of the following complicated skin and skin structure infections with MRSA (Methicillin-resistant Staphylococcus Aureus) either suspected or confirmed as the major cause of the infection:
- •major abscess requiring surgical incision and drainage;
- •infected burn (see exclusion criteria for important qualifications);
- •deep/extensive cellulitis;
- •infected ulcer (see exclusion criteria for important qualifications);
- •wound infections
- •Patients must be expected to require at least 7 days of intravenous antibiotic treatment.
排除标准
- •Received more than 24 hours of potentially effective systemic (IV/IM or PO) antibiotic therapy
- •Burns involving > 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis.
研究组 & 干预措施
Telavancin
Experimental
干预措施: Telavancin (Drug)
Vancomycin
Active Comparator
干预措施: Vancomycin (Drug)
结局指标
主要结局
Clinical Response
时间窗: 7 to 14 days after the last antibiotic dose
The Clinical Response for each patient was determined by the investigator by assessing the patient's clinical signs \& symptoms compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus AureusBacterial PneumoniaNCT00124020Cumberland Pharmaceuticals771
已完成
3 期
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus AureusBacterial PneumoniaNCT00107952Cumberland Pharmaceuticals761
已完成
3 期
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus AureusStaphylococcal Skin InfectionNCT00091819Cumberland Pharmaceuticals862
进行中（未招募）
3 期
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)Metastatic MelanomaUnresectable MelanomaNCT05155254IO Biotech407
Unknown
3 期
Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal InfectionsFungal InfectionsTinea PedisTinea CorporisTinea CrurisNCT01105013Laboratório Teuto Brasileiro S/A90